Valneva to Participate in Upcoming Investor Conferences
MWN-AI** Summary
Valneva SE, a specialty vaccine company, has announced participation in several investor conferences in the United States and Europe, scheduled for March and April 2026. During these events, CEO Thomas Lingelbach and CFO Peter Buhler will highlight the company's key value drivers and discuss forthcoming catalysts, particularly the anticipated top-line Phase 3 data release for VLA15, Valneva's Lyme disease vaccine candidate. Pfizer, Valneva's partner in this development, is expected to report these results in the first half of 2026.
The company's conference schedule includes a presentation at the TD Cowen 46th Annual Health Care Conference in Boston on March 4, followed by meetings at the Jefferies Biotech on the Beach Summit in Miami on March 10, and concluding with the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 15. Interested institutional investors are encouraged to arrange meetings with Valneva's management through their bank representatives.
Valneva’s focus is on developing and commercializing vaccines for infectious diseases to address unmet medical needs, leveraging deep expertise across various vaccine modalities. The company is noted for its strong track record, having successfully advanced several vaccines from research to market. Currently, it markets three proprietary travel vaccines and possesses a robust pipeline that includes the only Lyme disease vaccine candidate in advanced clinical development, in addition to the most clinically advanced Shigella vaccine candidate.
Investors are reminded that the press release contains forward-looking statements regarding Valneva's business prospects, including uncertainties linked to research and development timelines, regulatory approvals, and market competition. Any forward-looking statements should be interpreted with caution due to various risks that could impact actual outcomes. For further details, Valneva encourages visiting its website.
MWN-AI** Analysis
Investors looking into Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) should closely monitor upcoming investor conferences in March and April 2026. The presentations offer an insightful platform where CEO Thomas Lingelbach and CFO Peter Buhler will discuss critical developments within the company, particularly the topline Phase 3 data for its Lyme disease vaccine candidate, VLA15. This vaccine is highly anticipated, especially given the partnership with Pfizer, one of the leading pharmaceutical companies, enhancing the credibility and market potential of Valneva’s offerings.
Upcoming events, such as the TD Cowen Health Care Conference on March 4 and the Jefferies Biotech on the Beach Summit on March 10, present valuable opportunities for investors to gain insights directly from Valneva’s management. These conferences may lead to increased visibility and provide a platform to discuss market expectations, which could influence Valneva's share price positively if the Phase 3 data report is favorable.
Valneva's strategic focus on developing vaccines for unmet medical needs, including the only Lyme disease vaccine candidate in advanced clinical development, positions the company favorably in the specialty vaccine market. Given the company's commitment to addressing global public health challenges and its strong commercial pipeline, the firm demonstrates potential for substantial growth.
However, investors should remain aware of the inherent risks outlined in Valneva's forward-looking statements. Factors such as clinical trial outcomes, regulatory approvals, and competitive pressures could significantly impact the company's future trajectory.
In conclusion, while Valneva presents a compelling investment opportunity based on its innovative vaccine pipeline and market positioning, prospective investors should maintain a cautious approach, factoring in the outlined risks. Keeping an eye on upcoming conference takeaways will be crucial for gauging immediate investor sentiment and the company’s ongoing potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe.
CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company’s key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company’s Lyme disease vaccine candidate, which partner Pfizer expects to report in the first half of 2026.
The TD Cowen presentation will be webcast live and available as a replay in the “investor” section of the Valneva website at www.valneva.com.
TD Cowen 46th Annual Health Care Conference
Date/Time: March 4, 11:10am ET
Format: Presentation and investor meetings
Location: Boston, Massachusetts
Webcast Link: Click to Register
2026 Jefferies Biotech on the Beach Summit
Date/Time: March 10
Format: Investor meetings
Location: Miami, Florida
Van Lanschot Kempen Life Sciences Conference
Date/Time: April 15
Format: Investor meetings
Location: Amsterdam, The Netherlands
Attending institutional investors who would like to meet with Valneva management are asked to submit a request to their representative at the respective bank.
About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.
| Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelot-fontaine@valneva.com | Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com | | |
Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates, to regulatory approval of product candidates and review of existing products, and financial guidance including projected product sales, total revenue and total R&D investments. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Attachment
FAQ**
What are the anticipated key value drivers and upcoming catalysts for Valneva SE INRLF that will be discussed during the investor conferences in early March 2026?
How does Valneva SE INRLF plan to leverage the expected Phase 3 data readout for VLA15 in its strategic growth and commercial efforts in the specialty vaccine market?
What insights can investors expect from CEO Thomas Lingelbach and CFO Peter Buhler regarding Valneva SE INRLF's ongoing vaccine development pipeline at the TD Cowen conference?
How does Valneva SE INRLF's collaboration with Pfizer enhance the market potential for its Lyme disease vaccine candidate and overall portfolio strategy?
**MWN-AI FAQ is based on asking OpenAI questions about Valneva SE (OTC: INRLF).
NASDAQ: INRLF
INRLF Trading
0.2% G/L:
$5.10 Last:
1,000 Volume:
$5.10 Open:
